SCHEMBL376845

SCHEMBL376845

CC1(C)CCN(c2ccc(C(=O)O)cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 5/20 0.60
KDM4E B2RXH2 2/20 0.57
CHEK1 O14757 2/20 0.48
BCL2L1 Q07817 1/20 0.47
MGLL Q99685 1/20 0.46
ALDH1A1 P00352 6/20 0.46
HPGD P15428 3/20 0.46
HSD17B10 Q99714 3/20 0.46
TSHR P16473 3/20 0.46
MAPT P10636 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
TP53 P04637 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 1/20 0.46
ALOX15 P16050 1/20 0.46
STAT1 P42224 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
POLB P06746 2/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2947875 0.91 USP2 (0.54) USP2KDM4ECHEK1BCL2L1MGLL
SCHEMBL10222720 0.84 MGLL (0.46) USP2KDM4EMGLLALDH1A1HPGD
SCHEMBL10222721 0.84 MGLL (0.43) USP2KDM4EMGLLALDH1A1HPGD
SCHEMBL377181 0.84 CHRNA7 (0.55) USP2CHEK1MGLLALDH1A1MEN1
SCHEMBL2951912 0.84 KDM4E (0.64) USP2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2952332 0.83 USP2 (0.54) USP2KDM4ECHEK1BCL2L1ALDH1A1
SCHEMBL2946610 0.83 USP2 (0.54) USP2KDM4ECHEK1BCL2L1ALDH1A1
SCHEMBL23610369 0.82 KDM4E (0.71) USP2KDM4ECHEK1ALDH1A1HPGD
SCHEMBL17737082 0.82 KDM4E (0.71) USP2KDM4ECHEK1ALDH1A1HPGD
SCHEMBL1664911 0.82 KDM4E (0.57) USP2KDM4ECHEK1MGLLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11390610-B2 Piperazine derivatives as MAGL inhibitors HOFFMANN-LA ROCHE INC. (US) 2022-07-19 US disclosed
EP-3694840-B1 PIPERAZINE DERIVATIVES AS MAGL INHIBITORS HOFFMANN LA ROCHE (CH) 2021-08-04 EP disclosed
US-20200299277-A1 PIPERAZINE DERIVATIVES AS MAGL INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2020-09-24 US disclosed
US-8524947-B2 Acylsulfonamides and processes for producing the same UNIVERSITY OF SOUTH FLORIDA (US) 2013-09-03 US disclosed
US-8524947-B2 Acylsulfonamides and processes for producing the same UNIVERSITY OF SOUTH FLORIDA (US) 2013-09-03 US disclosed
US-20130203709-A1 ACYLSULFONAMIDES AND PROCESSES FOR PRODUCING THE SAME THE PENN STATE RESEARCH FOUNDATION (US) 2013-08-08 US disclosed
US-20130203709-A1 ACYLSULFONAMIDES AND PROCESSES FOR PRODUCING THE SAME THE PENN STATE RESEARCH FOUNDATION (US) 2013-08-08 US disclosed
EP-1888543-B1 APOPTOSIS PROMOTERS ABBOTT LAB (US) 2012-08-01 EP disclosed
WO-2012021486-A2 ACYLSULFONAMIDES AND PROCESSES FOR PRODUCING THE SAME UNIVERSITY OF SOUTH FLORIDA (US) 2012-02-16 WO disclosed
EP-1765778-B1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2012-01-25 EP disclosed
EP-1888543-A1 APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2008-02-20 EP disclosed
EP-1765778-A2 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2007-03-28 EP disclosed
WO-2006127364-A1 APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2006-11-30 WO disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 EP disclosed
WO-2005117543-A2 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2005-12-15 WO disclosed
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters ABBVIE INC. 2005-12-08 US disclosed
US-20040192681-A1 N-acylsulfonamide apoptosis promoters ABBVIE INC. 2004-09-30 US disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 US disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 USP2 1839/4885KDM4E 1911/4885CHEK1 3294/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 USP2 1819/4885KDM4E 1563/4885CHEK1 3163/4885
US-20040192681-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 USP2 1839/4885KDM4E 1911/4885CHEK1 3294/4885
US-11390610-B2 Piperazine derivatives as MAGL inhibitors MAGI3, PYM1, MAG USP2 2552/4885KDM4E 2009/4885CHEK1 4362/4885
US-20200299277-A1 PIPERAZINE DERIVATIVES AS MAGL INHIBITORS MAGI3, PYM1, MAG USP2 2552/4885KDM4E 2009/4885CHEK1 4362/4885
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters BAX, BCL2, BAD USP2 1129/4885KDM4E 1408/4885CHEK1 1071/4885
US-20130203709-A1 ACYLSULFONAMIDES AND PROCESSES FOR PRODUCING THE SAME BCL2, BCL2L2, BCL6 USP2 162/4885KDM4E 2852/4885CHEK1 3401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.